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Abstract
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is a global healthcare
problem. The purpose of this study was to characterize CA-MRSA clones and their distribution in Kuwait hospitals.
Methods: In total, 135 CA-MRSA isolates, carrying the SCCmec IV or V genetic elements, isolated in eight hospitals
were characterized using antibiogram, pulsed-field gel electrophoresis, multilocus sequence typing, and carriage of
genes for Panton-Valentine Leukocidin (PVL), capsular polysaccharides types (cap) 5 and 8, accessory genes
regulators (agr), Staphylococcal enterotoxins (SE) and toxic shock syndrome toxin 1 (tst).
Results: They were susceptible to vancomycin, teicoplanin and linezolid but resistant to kanamycin (62%), fusidic
acid (42.2%), tetracycline (39.3%), erythromycin and clindamycin (21.5%), gentamicin (5.9%), streptomycin (6.7%),
trimethoprim (5.9%), mupirocin (6.6%) and cadmium acetate (82.2%). They consisted of 10 pulsotypes with the
majority belonging to PFGE type I (51.1%), type II (22.2%), type IV (13.3%) and type III (3.7%). They belonged to 10
sequence types (ST) comprising ST80 (51.1%), ST30 (22.2%), ST5 (14.1%), ST1 (4.45), ST6 (3.7%), ST88 (1.5%), ST834
(1.5%), ST8 (0.7%), ST46 (0.7%) and ST950 (0.7%). Genes for PVL, cap 8, cap 5 and agr III, agr I and agr II were
detected in 61.5%, 77.3%, 20.7% and 62.2%, 17% and 8.1% of the isolates respectively. Nine (6.7%) isolates
contained tst while 103 isolates were positive for SE genes with sei (63.0%), seg (41.5%) and sed (29.6%) as the
common SE genes.
Conclusions: ST80-SCCmecIV was the most common CA-MRSA clone in Kuwait hospitals presenting new
challenges for infection control.
Background
Following their initial reports from patients in remote
communities with no access to healthcare facilities [1-3],
Community-associated methicillin resistant S. aureus
(CA-MRSA) has now been reported in many countries
and has become a global public health problem [4,5].
CA-MRSA carry the smaller staphylococcal chromo-
some cassette mec (SCCmec) types IV and V whereas
the larger SCCmec t y p e sI ,I Ia n dI I Ia r ep r e s e n ti n
MRSA traditionally associated with infections in health-
care facilities [4,5]. Initially, CA-MRSA were generally
more susceptible to non beta-lactam antibiotics than
healthcare associated MRSA [1,4,5]. However, some
CA-MRSA strains have now acquired multidrug resis-
tance [6-9].
The transmission of CA-MRSA was restricted to parti-
cular populations with distinctive risk factors such as
injections drug users and aboriginal communities [2,4,5].
However, since the 1990’s CA-MRSA has become wide-
spread and have been introduced from the community
into healthcare facilities where, in some instances, they
have become the dominant MRSA clones [10,11]. They
have demonstrated fitness to survive in healthcare facil-
ities. Consequently, some epidemic CA-MRSA clones
have emerged in several locations. These include the
USA300 clone which is dominant in USA and North
America [12], the ST30 (Oceanic clone) [13] and the
European ST80 clone [14-16].
CA-MRSA was first isolated in small numbers in
Kuwait hospitals in 2001 [17] when it constituted 1.8%
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Molecular typing of these isolates revealed ST30 and
ST80 as the common CA-MRSA clones [17]. Since
then, the prevalence of CA-MRSA has increased sub-
stantially and by 2005, 17% of all MRSA isolated in
Kuwait hospitals were CA-MRSA [18]. However, there
was no information on the clonal composition of these
strains. The objective of this study was to characterize
CA-MRSA obtained in Kuwait hospitals between 2005
and 2006 using SCCmec typing, PFGE and multi-locus
sequence typing to ascertain their clonal composition
and prevalence.
Materials and methods
MRSA isolates
From January 2005 to December 2006, the MRSA Refer-
ence Laboratory, located at the Department of Microbiol-
ogy, Faculty of Medicine, Kuwait University, Kuwait,
received 889 MRSA for typing. One hundred and thirty
five of these isolates were classified as CA-MRSA based on
their carriage of SCCmec IV or V genetic elements and
urease production. The 135 isolates originated from 131
patients located in eight hospitals. The isolates were col-
lected from Mubarak (MBH, 18 isolates), Amiri (AMH,31
isolates), Al-Sabah (ASH,29 isolates), Farwania (FAH; 12
isolates), Ibn Sina (ISH; 16 isolates), Al-Razi (ARH; 9 iso-
lates), Jahra (JH; 19 isolates) and the Maternity hospital
(MAT;1 isolate). from wound swabs (37 isolates),
abscesses (18 isolates), nasal swabs (18 isolates), ear swabs
(9 isolates), blood samples (5 isolates), groin (5 isolates),
throat swabs (5 isolates), urine samples (4 isolates), skin
swabs (3 isolates), tracheal aspirates (3 isolates), high vagi-
nal swabs (2 isolates), sputum (2 isolates) and eye swab (1
isolate). The source for 20 isolates was not provided. The
four isolates from the same patient were obtained from
four different sites and were all resistant to mupirocin [9].
Isolates were identified at the diagnostic laboratories and
confirmed as CA-MRSA at the MRSA Reference Labora-
tory using SCCmec typing and urease production. Pure
cultures were preserved in 40% (v/v) glycerol in brain
heart infusion broth (BHIB) at -20°C. Isolates were recov-
ered in BHIB, incubated at 37 °C, and sub-cultured on
brain heart infusion agar plates before testing.
Susceptibility to antibacterial agents
Susceptibility testing to antibacterial agents was
performed by the disk diffusion method [19] using oxa-
cillin, benzyl penicillin, cefoxitin, kanamycin, gentamicin,
erythromycin, clindamycin, chloramphenicol, tetracy-
cline, trimethoprim, fusidic acid, rifampicin, ciprofloxa-
cin, and linezolid. Susceptibility to fusidic acid was
interpreted following guidelines by the British Society
for Antimicrobial Chemotherapy [20]. Disks containing
(values per disk): cadmium acetate (50 μg), propamidine
isethionate (100 μg), mercuric chloride (109 μg) were
prepared in the laboratory. The results were interpreted
as reported previously [20]. Disk susceptibility testing
for mupirocin was performed with disks containing 5 μg
and 200 μg of mupirocin (Oxoid,B a s i n g s t o k e ,U K ) .
Growth to the edge of both the 5 μga n dt h e2 0 0μg
disks indicated high level resistance. Growth to edge of
the 5 μg disk alone defined low level resistance [21].
High-level mupirocin resistance was confirmed by MIC
determination and the detection of mupA gene by PCR
as described previously [9]. The MIC for oxacillin,
mupirocin, vancomycin and teicoplanin were deter-
mined with Etest strips (AB Biodisk, Solna, Sweden)
according to the manufacturer’s instructions. The Macro
method, using an inoculum equivalent to 2× McFarland
standard on brain heart infusion agar, was used to
determine MIC for vancomycin and teicoplanin [22]. S.
aureus strain ATCC25923 was used as quality control
strain for susceptibility testing. Methicillin resistance
was confirmed by detecting PBP 2a using a rapid latex
agglutination kit (Denka-Seiken, Japan) according to the
manufacturer’s instructions.
Urease production
Urease production was detected on Christensen’su r e a
agar slope after incubation at 35°C for 48 hours.
SCCmec and ccr typing
Staphylococcal cassette chromosome mec (SCCmec) typ-
ing and subtyping were performed as described pre-
viously [23]. The cassette chromosome recombinase (ccr
complex) types was determined using primers and
methods described previously [24]. Strain COL (SCCmec
type 1, ccr 2); XU642 (EMRSA-16, SCCmec type II, ccr
2); WBG525 (EMRSA-1, SCCmec type III), and K1814
(SCCmec type IV) and WBG 8318(SCCmec type V) as
controls.
Pulsed-field gel electrophoresis (PFGE)
Genomic DNA was prepared in agarose plugs as
described previously [25]. DNA was digested with 40 U
Sma I- (Biolabs, New England, USA) for 4 hr at 25°C.
Counter-clamped homogenous electric field (CHEF)
electrophoresis of digested chromosomal DNA was per-
formed in 1.2% agarose (pulse-field certified agarose,
B i o R a d ,U S A )a t6V / c mf o r2 1ha t1 4 ° C ,w i t hp u l s e
times of 5 s-40 s using a CHEF-DRIII system (BioRad).
Sma I digested chromosomal DNA of S. aureus strain
NCTC8325 was used as a molecular size marker. After
electrophoresis, the gel was stained with ethidium bro-
mide 0.5 μg/ml and photographed under ultraviolet illu-
mination. The chromosomal patterns were examined
visually and similarities of the PFGE patterns were
assigned using criteria published previously [26].
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Multilocus sequence typing (MLST) was performed by
following previously published protocols [27]. The
sequences of the seven house keeping genes (arc, aroE,
glpF, gmk, pta, tpi and yqiL)w e r ec o m p a r e dt oe x i s t i n g
sequences in the MLST database http://www.mlst.net
for assignment of allelic numbers. Sequence types (ST)
were assigned according to their allelic profiles.
Detection of virulence genes
DNA was extracted from S. aureus for PCR following a
protocol described previously [25]. PCR assays were
used to investigate the carriage of genes for accessory
gene regulator (agr) types I, II, III and IV using the pri-
mers and conditions published previously [28]. The
LukS-PV-lukF-PV gene which expresses Panton-Valentine
leucocidin (PVL) was amplified as described previously
[15]. The amplification of genes for capsular polysacchar-
ide (cap) types 5 and 8 were performed using primers
and conditions described previously [28]. Genes for the
staphylococcal enterotoxins, sea, seb, see, sed, sei, seh and
toxic shock syndrome gene, tst were amplified in multi-
plex PCR as described previously [25]. All PCR products
were analysed by agarose gel electrophoresis on 1.5%
agarose gels [25].
Statistics
Differences in the distribution of CA-MRSA clones were
assessed by Chi square test. A P-value of ≤ 0.05 was
considered significant.
Results
Staphylococcal cassette chromosome mec (SCCmec) and
ccr typing
The 135 MRSA isolates included in this study produced
urease and belonged to SCCmec type IV or type V.
Urease positivity was used to differentiate CA-MRSA
carrying the SCCmec IV genetic element from the
healthcare-associated epidemic MRSA-15 (EMRSA-15)
which also carries the SCCmec-IV genotype but does
not produce urease [29]. In total, 102 (75.6%) of the iso-
lates carried SCCmec type IV, 11 (8.1%) carried SCCmec
type IVa, 10 (7.4%) carried SCCmec type IVc and 12
(8.9%) the SCCmec type V genetic element. A total of
123 (91.1%) isolates consisting of the SCCmec type IV,
SCCmec IVa and SCCmec IVc isolates belonged to ccr
type 2 while the 12 SCCmec type V isolates belonged to
ccr type 5.
Antibacterial resistance of CA-MRSA isolates
All isolates were susceptible to vancomycin MIC: ≤ 2
μg/ml), teicoplanin MIC: ≤ 2 μg/ml), rifampicin and
linezolid but were resistant to oxacillin (MIC 8- > 256
μg/ml) and the antibacterial agents summarized in
Figure 1. There was a high prevalence of resistance to
cadmium acetate (82.2%), kanamycin (62.2%), fusidic
acid (42.2%), tetracycline (39.3%), erythromycin and
clindamycin (21.5%) and ciprofloxacin (20.7%). Sixty-
eight (50.4%) of the 135 CA-MRSA isolates were multi-
drug resistant (i.e. resistant to more than three classes
of non-beta lactam antibiotics tested).
Molecular typing of CA-MRSA isolates
Figure 2 shows the distribution of the 10 PFGE types
detected among the 135 isolates. The majority belonged
to PFGE type I or its five subtypes (51.1%), PFGE type
II and its two subtypes (23.7%), PFGE type IV and sub-
type IVa (13.3%). The other PFGE types occurred
sporadically.
MLST was performed on 28 isolates representing each
of the PFGE subtypes to determine their sequence types
(ST). MLST results showed extensive agreement with
PFGE except for ST5 that was detected in PFGE types
IV and IX. The isolate belonging to PFGE type IX was
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Figure 1 Antimicrobial resistance of CA-MRSA isolates.
Abbreviations: Cd, cadmium acetate; Kan, kanamycin; Fd, fusidic
acid; Tet, tetracycline; Erm, erythromycin; Cip, ciprofloxacin; Tp,
trimethoprim; Gen, gentamicin; mupH, high-level mupirocin; Chl,
chloramphenicol.
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Figure 2 Distribution of PFGE types among CA-MRSA isolates.
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S T 9 5 0( aS L Vo fS T 5a ttpi). Based on the distribution
of sequence types according to their PFGE patterns, 69
(51.1%) of the 135 isolates were ST80. This was followed
by ST30 (22.2%), ST5 (14.1%), ST1 (4.4%), ST6 (3.7%),
ST88 (1.5%), ST834 (1.5%), ST8 (0.7%), ST46 (0.7%) and
ST950 (0.7%). As shown in Table 1, the ST80 clone was
present in seven of the eight hospitals. ST30 and ST5
clones were detected in six hospitals while ST1 clone
was present in five hospitals. The other clones occurred
sporadically. When compared with the distribution of
CA-MRSA clones prevalent in Kuwait hospitals in 2001-
2003 [17], the proportion of ST80 isolates increased
from 38.5% in 2001-2003 [17] to 51.1% (P = 0.29), while
the proportion of ST30 isolates decreased from 30.8% in
2001-2003 to 23.7% (P = 0.45)
Detection of virulence-associated genes
None of the isolates was positive for agr type IV. How-
ever, they contained genes for agr III (62.2%), agr I
(17%), agr II (8.1%), capsular polysaccharides types 8
(77.3%) and type 5 (20.7%). Three (2.2%) isolates yielded
negative result for both cap 5 and cap 8.T h eP V Lg e n e
was detected in 61.5% of the isolates.
In total, 103 (76.3%) isolates yielded positive results
for sea (10.4%), seb (3.7%), sec (4.4%), sed (29.6%), seg
(41.5%), seh (1.5%), sei (63.0%) and tst (6.7%). None of
the isolates was positive for see. Twenty-seven (26.2%),
52 (50.5%), 17 (16.5%) and seven (6.8%), of the 103 iso-
lates were positive for single, two, three and four SE
genes respectively. Twenty-three isolates contained seg
and sei while 20 isolates contained sed and sei.
Diversity of ST80-CA-MRSA isolates
Table 2 summarizes the phenotypic and genotypic char-
acteristics of the ST80 isolates. The 69 ST80 isolates
had related but not identical PFGE patterns. Although
39 of the isolates had identical PFGE patterns (PFGE
type I), the remaining 30 isolates were grouped into five
subtypes: Ia (2 isolates), Ib (10 isolates), Ic (1 isolate), Id
(2 isolates and Ie (15 isolates).
The ST80 isolates expressed low oxacillin MIC (MIC
8-64 μg/ml). They also expressed diverse resistance
phenotypes. In total, 23 of the 69 isolates were resistant to
kanamycin, tetracycline and fusidic acid, that are tradition-
ally associated with ST80-SCCmec-IV isolates (17, 28). Of
these 23 isolates, 15 expressed additional resistance to one
or more of ciprofloxacin, gentamicin, erythromycin, tri-
methoprim, mupirocin and chloramphenicol. Further-
more, some of the isolates were susceptible to kanamycin,
tetracycline and fusidic acid that usually characterize
ST80-SCCmec-IV isolates. Ten isolates were resistant to
cadmium acetate but were susceptible to all of the non
beta-lactam agents tested. Forty one (59.4%) of the 69 iso-
lates were multiresistant (resistance to more than three
antibiotic classes).
All ST80 isolates carried genes for capsular polysac-
charide types 8 and agr III but varied in the carriage of
other virulence-associated genes. As presented in Table
2, 58 (84.0%) and 49 (71.0%) of the 69 isolates were
positive for PVL and SE genes respectively. Fifteen iso-
lates were positive for single SE gene while 30 were
positive for two or more SE genes. The majority of the
isolates were positive for sei (77.6%) and seg (36.7%).
Nineteen (27.9%) isolates were positive for sed and sei,
and ten (14.7%) were positive for seg and sei.T w oi s o -
lates were positive for tst.
Discussion
This study characterized ten different CA-MRSA
clones in Kuwait hospitals with ST80 (51.1%) and
ST30 (22.2%) as the major CA-MRSA clones similar to
the composition of CA-MRSA isolates circulating in
Kuwait hospitals in 2001-2003 [17]. However, results
of this study differ from the previous study in three
aspects. The 2001-2003 isolates consisted of five CA-
MRSA clones whereas the present study has identified
ten CA-MRSA clones. This represents a substantial
increase in the number of CA-MRSA clones and con-
firms their expansion in Kuwait hospitals. Secondly,
whereas the proportion of ST80 isolates increased
from 38.5% in 2001-2003 [17] to 51.1% in the present
study, the proportion of ST30 isolates decreased from
30.8% in 2001-2003 to 22.2%. However, these changes
were not statistically significant. The proportion of
ST5 isolates has also increased from 7.7% in 2001-
2003 to 14.1%. Thirdly, new clones, ST46, ST88, ST1,
ST834 and ST950, appeared for the first time in
Kuwait in this study. In contrast, strains belonging to
ST361 and ST728 that were present in 2001-2003 were
absent in this study highlighting the evolving nature of
CA-MRSA isolates.
Table 1 Distribution of CA-MRSA clones in Kuwait
hospitals
ST AMH ARH ASH FAH MBH JH ISH MAT Total %
80 12 4 8 10 14 11 10 - 69 51.1
30 10 - 11 - 2 3 3 1 30 22.2
5347-1 3 1 -1 9 1 4
1 1 - 1 2 1 - 1 - 6 4.4
6 1 2 - - 2 - - - 5 3.7
88 - - - 2 - - - - 2 1.5
8 1 - - - - - - - 1 0.7
46 1 - - - - - - - 1 0.7
950 1 - - - - - - - 1 0.7
834 - - - - - - 1 - 1 0.7
Total 30 10 27 14 20 17 16 1 135
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acetate, kanamycin, fusidic acid, tetracycline, erythromy-
cin, clindamycin and ciprofloxacin with 50.4% of the iso-
lates being multiresistant to non-beta lactam antibiotics.
Multiresistant-CA-MRSA isolates have also been
reported among CA-MRSA clones isolated in Brazil [7],
Japan [8] and USA [12].
We detected genes for PVL in 61.5% of the CA-MRSA
isolates distributed among different sequence types as
has also been reported in other countries [10,12,30,31].
Table 2 Characteristics of ST80 CA-MRSA isolates
Virulence-associated genes (# of positives)
# of isolates PFGE SCCmec Antibiogram PVL SE tst
4 I IV Cd, Kan, Tet, Fd + (2) sei,(2) sed (2)- -
2 Ib IV Cd, Kan, Tet, Fd - sei (1), sed (1), seg (1) -
1 Id IV Cd, Kan, Tet, Fd + - -
2 Ie IV Cd, Kan, Tet, Fd + - -
3 I IV Cd, Kan, Tet, Fd, Cip + (2) sei (2), sed (1) -
2 Ie IV Cd, Kan, Tet, Fd, Cip + (2) sei (2), sed (2) -
1 I Iva Cd, Kan, Tet, Fd, Cip, Gen + sei, seg ,-
4 Ib IV Cd, Kan, Tet, Fd, Mup + seg (4) -
1 I IV Cd, Kan, Tet, Fd, Tp + seg -
1 I IV Cd, Kan, Tet, Fd, Erm + sei -
1 Ie IV Cd, Kan, Tet, Fd, Gen - seg -
2 I IV Cd, Kan, Fd, Erm, Cip + (1) sei (1), seg (1) -
1 I IV Cd, Kan, Fd, Erm, Cip, Chl - sed -
1 I IV Cd, Kan, Fd, Cip - sei -
1 Ib IV Cd, Kan, Fd, Cip + sei, seg -
1 I IV Cd, Kan, Fd, Gen + seg -
1 Ib IV Cd, Kan, Fd, Gen - - -
1 I IV Cd, Kan, Fd + sei -
1 Ib IV Cd, Kan, Fd + sei, sed +
3 I IV Cd, Kan + (3) sei,(2) sed (2) -
1 Ia IV Cd, Kan + sei -
1 Ie IV Cd, Kan, Erm, Tet - - -
1 Ie IV Cd, Kan, Erm, Cip - sei, sed -
2 I IV Cd, Kan, Erm, Cip + (1) Sei (1), seg (1) -
1 Ia IV Cd, Kan, Erm, Cip, Chl + - -
1 I IV Cd, Kan, Cip, Tp, Gen + sei -
7 I IV Cd + sei (2), sed (1), seg (1)
1I e I V C d + - -
2I b I V C d - sei (2), seg (2), sec(1) -
3 I IV Cd, Erm + sei (3), seg (2), Sed (1) -
1 I IV Cd, Fd + - -
2 I IV Cd, Tet + Sei (1), seg(2) -
1 Ic IV Cd, Tet, Fd, Chl, Tp, Cip, Erm - sei, sed, seg -
1 I IV Erm, Cip + sei, seb, seg -
1 Ie IVc Kan, Tet, Fd + - -
1 Ie IV Kan, Tet, Fd + sei, sed -
1 Ib IV Kan + sei, sed -
2 Ie IV Kan + (2) sei (1), sed(1) -
1 Ie IV Kan, Erm + - -
1 Ie IV Tet - sei, sed, sea -
1I d I V - + sea -
1I I V - + sei +
1I e I V - - - -
Abbreviations:Cd, cadmium acetate; Cip, ciprofloxacin; Chl. chloramphenicol; Erm, erythromycin; Fd, fusidic acid; Gen, gentamicin; Kan, kanamycin; Tet,
tetracycline; Tp, trimethoprim.
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MRSA which is similar to results of studies in Belgium,
France, Japan and Switzerland where the majority of
their CA-MRSA isolates belong to agr type III [12,16]
and possessed capsular polysaccharide type 8 [31]. How-
ever, whereas sei (63%) was the most common SE gene
among our CA-MRSA isolates, seg was the most abun-
dant SE gene in MRSA obtained in Ireland [30]. We
observed the co presence of seg and sei in our isolates
which has also been reported in CAMRSA studied in
USA [32]. Furthermore, similar to the observation in
CA-MRSA isolates from Ireland [30] and USA [32],
none of our CA-MRSA isolates was positive for see.
However, in contrast to the low prevalence of tst (6.7%)
in this study, Rossney et al., [30] detected tst in 24% of
CA-MRSA isolates in Ireland.
The ST80-SCCmec-IV clone has been the dominant
CA-MRSA clone in European countries for some time
[14,16]. With a prevalence of 51.1% of the CA-MRSA,
the ST80 clone was the most common CA-MRSA clone
in Kuwait hospitals. However, our ST80 isolates varied
phenotypically. Although so m ew e r er e s i s t a n tt ok a n a -
mycin, tetracycline and fusidic acid similar to the resis-
tance pattern of the European ST80 clone [14,16], the
results in Table 2 showed that some of our ST80 iso-
lates had varied resistance patterns with some being sus-
ceptible to kanamycin, tetracycline and fusidic acid.
They were also heterogeneous in their enterotoxin gene
profiles. Remarkably, our ST80 isolates contained sed,
sei, seg, seb, seh and sea, singly or in combinations. In
contrast, studies from the Netherlands [16] detected
only seh in their ST80 isolates. The detection of genes
for different SEs in this study suggests that ST80 isolates
m a yb ea c q u i r i n gg e n e sf o rdifferent SEs probably due
to the acquisition of toxin-carrying bacteriophages [33].
In addition, 11 (16%) of the 69 ST80 isolates were nega-
tive for PVL genes. In a previous study, a small number
( 5o f3 5 7 )o fS T 8 0i s o l a t e so b t a i n e df r o mA l g e r i a ,
Switzerland and France also lacked genes for PVL [34].
It is uncertain whether these isolates arose from PVL
positive isolates due to the loss of the PVL phage or
represents native ST80 backgrounds that had not pre-
viously acquired the PVL phage.
The dominance of the ST80 and ST30 CA-MRSA
clones in Kuwait hospitals in 2001-2003 was attributed
to their importation into the country by returning
patients who sought medical care abroad, or expatriate
staff from countries where these clones are prevalent
[17]. Their presence in seven of the eight hospitals dur-
ing the current study suggests that local transmission is
also occurring. In addition, the diverse phenotypes
observed with the ST80 isolates suggest that local var-
iants of ST80 clones are emerging in Kuwait.
Conclusion
This study has shown that the ST80-SCCmec-IV clone
was the most common CA-MRSA clone in Kuwait hos-
pitals in 2005-2006. However, other sequence types such
as ST5 and ST6 also appeared. Most of the isolates were
multi-resistant to antibacterial agents and harbored
genes for different virulence factors. The successful
expansion of CA-MRSA clones in Kuwait hospitals calls
for novel approaches in infection control measures to
control their spread.
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